Migrevention

Cover Block

Attribute	Detail
Company Name	Migrevention
Tagline	Estonia-based digital headache clinic with app for migraine self-management and provider tools.
Headquarters	Tallinn, Estonia
Founded	2020
Stage	Pre-Seed
Business Model	B2B2C
Industry	Healthtech
Technology	Software (Non-AI)
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Pre-seed (total disclosed ~$737,000)

Links

• Website: https://migrevention.com/
• LinkedIn: https://ee.linkedin.com/company/migrevention

The Short Version

Migrevention is building a fully digital headache clinic, a novel approach in a chronic condition space historically underserved by scalable, evidence-based digital tools [Invest in Estonia, Jan 2022]. Founded in 2020, the Estonia-based startup aims to wedge into the migraine management market through a Class I medical device app for patient diaries and asynchronous nurse counseling, positioning itself as a hybrid B2B2C service for both patients and providers [EU-Startups, Jan 2022]. The founding team includes a clinical lead with academic neurology credentials, which grounds the product's development in medical research rather than consumer wellness trends [ResearchGate].

In January 2022, the company closed a €355,000 pre-seed round led by angel investor Dag Nurm, a sum that has supported an ongoing clinical intervention study in partnership with Tartu University Hospital [Invest in Estonia, Jan 2022]. The business model appears to target healthcare systems and specialists seeking to manage patient populations more efficiently. Over the next 12-18 months, the key watchpoints are the publication of results from its clinical study, which will serve as a critical validation milestone, and any subsequent commercial partnerships or funding announcements that would signal traction beyond its initial research phase.

Data Accuracy: YELLOW -- Core facts (founding, funding round, product description) are corroborated by multiple regional press outlets; clinical study and team details are from single sources.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B2C
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Pre-seed (total disclosed ~$737,000)

The Company in Brief

Migrevention was founded in Tallinn, Estonia in 2020 as a digital health venture, conceived as a fully digital clinic for managing primary headaches like migraines [Invest in Estonia, Jan 2022]. The founding team, which includes Katrina Laks as CEO and neurologist Mark Braschinsky as Chief Scientific Officer, structured the company to bridge clinical expertise with software delivery, aiming to provide evidence-based tools outside traditional care settings [Health Founders, ~2021].

Key operational milestones have centered on clinical validation and early funding. In January 2022, the company closed a €355,000 pre-seed round led by investor Dag Nurm, a transaction that coincided with the launch of a clinical intervention study in partnership with Tartu University Hospital [Invest in Estonia, Jan 2022] [EU-Startups, Jan 2022]. This study, designed to compare digitally delivered treatment with conventional care, represents the primary public indicator of the company's research and development progress [PLOS Digital Health].

Data Accuracy: YELLOW -- Founding details and 2022 funding confirmed by two press sources; subsequent activity not corroborated.

What They Have Built

Migrevention's core offering is a Class I medical device application that functions as a fully digital headache clinic. The product is designed for the self-management of primary headaches, such as migraines, and integrates a suite of evidence-based tools. The patient-facing app provides a digital diary for symptom tracking and self-monitoring, paired with asynchronous chat access to a nurse for counseling [Invest in Estonia, Jan 2022]. A separate provider-facing interface, described as a patient manager, is intended to give healthcare professionals oversight of their patients' progress [Invest in Estonia, Jan 2022]. The company's stated wedge is using these digital diaries and counseling tools to enable disease management that is ten times more efficient than conventional methods [Invest in Estonia, Jan 2022].

Beyond the core clinical functionality, the company has made a public commitment to donate 5% of its annual revenue to migraine-related non-profit organizations and research initiatives [Health Founders, ~2021]. The technology stack is not detailed in public materials, but the presence of a CTO (Karl Käis) and the nature of the product suggest a standard mobile and web application architecture. The product is currently the subject of a clinical intervention study being conducted in partnership with Tartu University Hospital, which is intended to compare the digitally delivered treatment against conventional care [Invest in Estonia, Jan 2022] [PLOS Digital Health].

Data Accuracy: YELLOW -- Product description is consistent across press coverage and a founder interview, but key performance claims and technical specifications are not independently verified.

Market Research and Opportunity

The market for digital migraine management tools is being reshaped by a persistent gap in accessible, evidence-based care and a growing patient population seeking alternatives to episodic treatment. Migrevention's thesis targets a specific wedge within this broader digital health landscape, aiming to prove that a fully digital clinic can manage chronic conditions more efficiently than traditional in-person visits.

Migraine is the second leading cause of global disability, affecting over one billion people worldwide [PLOS Digital Health]. The global migraine treatment market was valued at $3.1 billion in 2020 and is projected to reach $5.6 billion by 2028, a compound annual growth rate of 7.8% (estimated) [Migraine Buddy]. These figures represent the total pharmaceutical and therapeutic market, providing an analogous scale for the problem Migrevention addresses. The company's immediate serviceable market is narrower, focusing on patients with primary headaches who are digitally literate and seeking structured, non-pharmacological management tools.

Metric	Value
Global Migraine Treatment Market 2020	$3.1B
Projected Market 2028	$5.6B

Data Accuracy: YELLOW -- Market sizing is drawn from an adjacent therapeutic market report cited by a competitor; the specific SAM for digital headache clinics is not publicly quantified.

Who Else Is Fighting for This

Migrevention enters a fragmented market for migraine management where digital solutions range from patient-centric tracking apps to provider-focused clinical tools, positioning itself as a hybrid digital clinic that attempts to bridge both sides.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Migrevention	B2B2C digital headache clinic with Class I medical device app, patient diaries, and provider tools.	Pre-seed (~$737k total disclosed). Clinical study with Tartu University Hospital.	Hybrid model combining patient self-management with asynchronous clinician support and a provider-facing dashboard.	[Invest in Estonia, Jan 2022]
Migraine Buddy	Consumer-focused migraine tracking and diary app with a large user community.	Part of Healint, a Singapore-based digital health company.	Massive, established global user base for symptom logging; strong brand recognition among patients.	[Migraine Buddy]
Curelator	Digital therapeutic platform for migraine prevention, offering personalized trigger identification.	Privately held.	Focus on predictive analytics and personalized prevention plans based on user-reported data.	[Crunchbase]

Data Accuracy: YELLOW -- Competitor profiles are based on public positioning; funding and scale for Migraine Buddy and Curelator are not deeply detailed in captured sources. Migrevention's differentiation is cited from a single 2022 article.

Opportunity

If Migrevention can prove its digital clinic model improves outcomes and lowers costs, it could capture a meaningful share of the underserved global migraine management market. The headline opportunity for Migrevention is to become the first validated, fully digital standard of care for primary headache disorders, a category historically reliant on episodic in-person consultations. The company's positioning as a "digital headache clinic" integrating a Class I medical device app with asynchronous clinical support aims to directly address the chronic care gap [Invest in Estonia, Jan 2022]. Its ongoing intervention study with Tartu University Hospital, designed to compare digital delivery against conventional treatment, provides a direct pathway to generating the evidence-based validation required for broader healthcare system adoption [PLOS Digital Health].

Data Accuracy: YELLOW -- The core opportunity thesis is supported by the company's stated model and ongoing clinical study, but key traction metrics validating the flywheel or commercial adoption are not publicly available.

Sources

1. [Invest in Estonia, Jan 2022] Estonian startup Migrevention builds a digital clinic to save you from headache | https://investinestonia.com/estonian-startup-migrevention-builds-a-digital-clinic-to-save-you-from-headache/
2. [EU-Startups, Jan 2022] Estonian migraine treatment app Migrevention completes pre-seed round and enters clinical trial | https://www.eu-startups.com/2022/01/estonian-migraine-treatment-app-migrevention-completes-pre-seed-round-and-enters-clinical-trial/
3. [Health Founders, ~2021] Meet the Founders: Migrevention | https://healthfounders.ee/migrevention/
4. [ResearchGate] Mark BRASCHINSKY | Lecturer | MD, PhD | University of Tartu, Tartu | Department of Neurology and Neurosurgery (ARNR) | Research profile | https://www.researchgate.net/profile/Mark-Braschinsky
5. [PLOS Digital Health] Implementing a digital solution for patients with migraine,Developing a methodology for comparing digitally delivered treatment with conventional treatment: A study protocol | https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0000295
6. [Migraine Buddy] Innovative Migraine Management Tools: Wearables and Digital Health - Migraine Buddy | https://migrainebuddy.com/innovative-migraine-management-tools-wearables-and-digital-health/
7. [Crunchbase] Migrevention - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/migrevention